{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000020","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.303002+00:00","generated_at":"2026-05-23T02:13:50.059600+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere's FILSPARI gets standard EU marketing authorization; receives $17.5M milestone","bullets":["European Commission converts conditional approval to standard MA for FILSPARI (sparsentan) for primary IgAN in all EU member states, plus Iceland, Liechtenstein, Norway.","UK MHRA also converted to standard approval on April 15, 2025.","Company receives $17.5M milestone payment from CSL Vifor; eligible for additional market access and sales-based milestones.","Approval based on Phase 3 PROTECT Study showing significant slowing of kidney function decline vs. irbesartan."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000020","json":"https://secwatch.observer/filing/0001438533-25-000020.json","markdown":"https://secwatch.observer/filing/0001438533-25-000020.md","text":"https://secwatch.observer/filing/0001438533-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000020/0001438533-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000020/tvtx-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:13:50.059600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}